Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
EDP-323 by Enanta Pharmaceuticals for Respiratory Syncytial Virus (RSV) Infections: Likelihood of Approval
EDP-323 is under clinical development by Enanta Pharmaceuticals and currently in Phase I for Respiratory Syncytial Virus (RSV) Infections. According...